LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Prior antiretroviral therapy experience protects against zidovudine-related anaemia.

Publication

Author(s):

Huffam SE, Srasuebkul P, Zhou J, Calmy A, Saphonn V, Kaldor JM, Ditangco R; TREAT Asia HIV Observational Database (TAHOD).

Pub Title:

Prior antiretroviral therapy experience protects against zidovudine-related anaemia.

Pub Date:

Oct 31 2007

Pub Region(s):

Asia-Pacific

Journal Issue:

7

Page Number:
465-71

Journal:

Title: 
HIV Medicine
Link: 
http://onlinelibrary.wiley.com/doi/10.1111/j.1468-1293.2007.00498.x/abstract

PubMed: 17760739
Pub PDF: PDF icon 17760739.pdf

Abstract
OBJECTIVE
: We investigated the use of antiretroviral therapy regimens containing zidovudine or stavudine, using data from the TREAT Asia HIV Observational Database (TAHOD), a multicentre, prospective, observational study of an HIV-infected cohort in the Asia-Pacific Region.

METHODS: A proportional hazards regression analysis of factors associated with the time to discontinuation of initial regimens containing zidovudine or stavudine and a logistic regression analysis to identify factors associated with a diagnosis of anaemia within 6 months of commencement of zidovudine in initial or subsequent regimens were performed.

RESULTS: Patients who started zidovudine were more likely to stop within the first 9 months of treatment than those who started on stavudine; the reverse was true after 9 months. Anaemia (haemoglobin<or=10 g/dL) occurred in the first 6 months in 57 of 433 patients (13%) on zidovudine. Baseline anaemia was the strongest predictive factor for subsequent anaemia, and prior antiretroviral therapy (ART) experience was protective for development of anaemia.

CONCLUSIONS: These data support baseline haemoglobin testing and avoidance of zidovudine if the patient is anaemic. The protective effect of prior ART for development of anaemia on zidovudine supports the short-term safety of a stavudine to zidovudine switch with routine haemoglobin monitoring in this cohort. Further studies in resource-poor settings of longer term efficacy and toxicities of ART switch strategies are needed.

PMID: 17760739 [PubMed - indexed for MEDLINE]

 

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Huffam SE, Srasuebkul P, Zhou J, Calmy A, Saphonn V, Kaldor JM, Ditangco R; TREAT Asia HIV Observational Database (TAHOD). Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med. 2007 Oct;8(7):465-71. PubMed PMID: 17760739.